- Wegovy News Pushes Novo Nordisk Stock Higher Barron’s
- Novo Nordisk shares pop after Wegovy receives U.S. approval for liver disease CNBC
- Wegovy Gets F.D.A. Approval for MASH The New York Times
- Novo’s Wegovy becomes first GLP-1 drug approved for MASH BioPharma Dive
- FDA Approves Novo Nordisk’s Wegovy for Liver Disease The Wall Street Journal
Source link
